Skip to main content
Teaser
Kapseln
Teaser
Teaser

vaccine

Carboxymethyl-beta-glucan/chitosan nanoparticles for antigen delivery

Various polysaccharides such as chitosan and β-glucan possess immunological properties that are advantageous for vaccine adjuvants. Therefore, in the presented study, chitosan and carboxymethyl-β-glucan were combined as nanoparticles, coupled to the model antigen ovalbumin as vaccine adjuvant and investigated in vivo in a mouse model.

Chitosan in an inhalable nanovaccine against SARS-CoV-2

The global corona pandemic requires effective vaccines to achieve herd immunity. In the study presented here, an inhalable chitosan-based nanovaccine containing the viral spike protein (S) was developed to specifically induce immunity at the mucosal sites of the respiratory tract.

Chitosan as antigen platform for pneumococcal vaccines

Chitosan shows great potential as part of drug release systems of orally administered drug formulations. Another interesting use is as an antigen platform for vaccines. We present an article in which pneumococcal membrane protein-loaded chitosan capsules were prepared and evaluated for their efficacy for a nasally administered vaccine.

Chitosan against Corona? Substituted chitosan as effective inhibitor of SARS-CoV-2 and MERS-CoV

The new corona virus SARS-CoV-2 has spread globally, originating from China since the beginning of the year. The pathogen causes the lung disease Covid-19 and has been classified as a pandemic since March 11, 2020. Researchers around the world are working on the development of effective vaccinations and drugs. A current study examined the antiviral effectiveness of HTCC (N- (2-hydroxypropyl) -3-trimethylammonium chitosan chloride) in vitro and ex vivo against the new coronavirus SARS-CoV-2 and MERS-CoV.

The world of chitosan in 2016 & chitosan as adjuvant in vaccines

At the end of the year we want to give you an overview about chitosan-related publications in 2016 and in the second part we focus on a quite different application of chitosan – how human and veterinary vaccines could benefit from chitosan as adjuvant.

Publications in March and April 2013

In March and April 262 publications were released about Chitosan, which mainly focused on animal and human studies, nanoparticles and pharmaceutical preparations. The most successful nations in the field of chitosan research have been: China (83 articles), India (31) and USA (22).

Publications in December 2011

Overall, 122 articles about chitosan were published worldwide in December 2011. China was the top publisher of the month again.

China:     32 articles
Indien:     9 articles
USA:     8 articles

Contact

  • Heppe Medical Chitosan GmbH
    Heinrich-Damerow-Strasse 1
    06120 Halle (Saale)
    Germany
  • Tel.: +49 (0) 345 27 996 300
    Fax: +49 (0) 345 27 996 378
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.